Use of Oral Anticoagulation for Patients with ESRD on Hemodialysis with Atrial Fibrillation: Verdict 1.
作者信息
Bansal Nisha
机构信息
Division of Nephrology, Kidney Research Institute, University of Washington, Seattle, Washington.
出版信息
Clin J Am Soc Nephrol. 2016 Nov 7;11(11):2093-2094. doi: 10.2215/CJN.08610816. Epub 2016 Oct 25.
Abstract
摘要
相似文献
1
Use of Oral Anticoagulation for Patients with ESRD on Hemodialysis with Atrial Fibrillation: Verdict 1.口服抗凝药在接受血液透析的终末期肾病合并心房颤动患者中的应用：结论1
Clin J Am Soc Nephrol. 2016 Nov 7;11(11):2093-2094. doi: 10.2215/CJN.08610816. Epub 2016 Oct 25.
2
Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Verdict 2.终末期肾病患者心房颤动管理中口服抗凝药的应用：裁决2
Clin J Am Soc Nephrol. 2016 Nov 7;11(11):2095-2096. doi: 10.2215/CJN.09470916. Epub 2016 Oct 25.
3
Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Verdict 3.终末期肾病患者心房颤动管理中口服抗凝药的应用：裁决3
Clin J Am Soc Nephrol. 2016 Nov 7;11(11):2097. doi: 10.2215/CJN.09230816. Epub 2016 Oct 25.
4
Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Introduction.终末期肾病患者心房颤动管理中口服抗凝药的应用：引言。
Clin J Am Soc Nephrol. 2016 Nov 7;11(11):2078. doi: 10.2215/CJN.09700916.
5
Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Pro.终末期肾病患者心房颤动管理中口服抗凝药的应用：专家共识
Clin J Am Soc Nephrol. 2016 Nov 7;11(11):2079-2084. doi: 10.2215/CJN.02680316. Epub 2016 Oct 25.
6
Stroke prevention in atrial fibrillation patients with chronic kidney disease.房颤合并慢性肾脏病患者的卒中预防。
Can J Cardiol. 2013 Jul;29(7 Suppl):S71-8. doi: 10.1016/j.cjca.2013.04.005.
7
Oral anticoagulation in end-stage renal disease and atrial fibrillation: is it time to just say no to drugs?终末期肾病合并心房颤动的口服抗凝治疗：是时候对药物说“不”了吗？
Heart. 2017 Jun;103(11):807-808. doi: 10.1136/heartjnl-2016-310540. Epub 2017 Jan 9.
8
Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Con.终末期肾病患者心房颤动管理中口服抗凝药的应用：反对观点
Clin J Am Soc Nephrol. 2016 Nov 7;11(11):2085-2092. doi: 10.2215/CJN.03200316. Epub 2016 Oct 25.
9
Oral Anticoagulants to Prevent Stroke in Nonvalvular Atrial Fibrillation in Patients With CKD Stage 5D: An NKF-KDOQI Controversies Report.口服抗凝剂预防 CKD 5D 期非瓣膜性心房颤动患者卒中：NKF-KDOQI 争议报告。
Am J Kidney Dis. 2017 Dec;70(6):859-868. doi: 10.1053/j.ajkd.2017.08.003. Epub 2017 Sep 21.
10
The intersection of risk and benefit: is warfarin anticoagulation suitable for atrial fibrillation in patients on hemodialysis?
Chest. 2009 Oct;136(4):1128-1133. doi: 10.1378/chest.09-0730.
引用本文的文献
1
Bleeding and Thrombotic Events in Hemodialysis Patients with Atrial Fibrillation on Anticoagulation and Antiplatelet Therapy: A 24-Month Cohort Study.抗凝和抗血小板治疗的透析伴房颤患者出血和血栓栓塞事件：一项 24 个月的队列研究。
Medicina (Kaunas). 2024 Oct 27;60(11):1760. doi: 10.3390/medicina60111760.
2
Anticoagulation in CKD and ESRD.慢性肾脏病和终末期肾病患者的抗凝治疗。
J Nephrol. 2019 Oct;32(5):719-731. doi: 10.1007/s40620-019-00592-4. Epub 2019 Jan 28.
3
Relation of Race, Apparent Disability, and Stroke Risk With Warfarin Prescribing for Atrial Fibrillation in Patients Receiving Maintenance Hemodialysis.种族、明显残疾与房颤合并维持性血液透析患者华法林处方相关性研究。
Am J Cardiol. 2019 Feb 15;123(4):598-604. doi: 10.1016/j.amjcard.2018.11.020. Epub 2018 Nov 24.
4
Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study.在慢性血液透析的心房颤动患者中比较阿哌沙班与苯丙香豆素的随机对照试验的设计与原理：AXADIA-AFNET 8研究
BMJ Open. 2018 Sep 10;8(9):e022690. doi: 10.1136/bmjopen-2018-022690.
5
Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease.口服抗凝药物在肾脏病患者中的临床药理学。
Clin J Am Soc Nephrol. 2019 Feb 7;14(2):278-287. doi: 10.2215/CJN.02170218. Epub 2018 May 25.
Zotero 插件